The Trebla Times - September Edition
Welcome to the September edition of The Trebla Times!
This month tested the biotech and pharma market, but history reminds us that recoveries are even more powerful. Market shifts and challenges spark reinvention, sharpen focus, and fuel the next wave of breakthroughs! What doesn’t kill us makes us stronger.
T R E N D S
Here’s what we’re seeing in the biotech hiring landscape right now
🪓Big Biotech, Big Hits
This month, the biotech sector saw 14 workforce reductions with many coming from household names like Novo Nordisk, Novartis, and BMS. The trend underscores ongoing pressures even among the industry’s biggest players.
September witnessed a surge in mergers and acquisitions across the biotech sector with the larger hitters snatching up companies with promising Phase 3 programs.
Roche's $3.5 Billion Deal for 89bio - The acquisition focuses on 89bio's phase 3 program for MASH.
Pfizer's $7.2 Billion Acquisition of Metsera – Metsera is a company developing GLP-1 receptor agonists for metabolic disorders, expanding Pfizer’s push to expand it’s metabolic disease portfolio
🪑Back to the Benches
It looks like remote work in biotech is slowly taking a back seat. Over the last quarter, 73% of our open roles have required an onsite presence, showing a noticeable shift toward in-person work. Fewer candidates, means fiercer competition – how do you plan to stand out?
T R E B L A
A behind-the-scenes look at what Trebla’s been up to this month
💰 Offers for the month
Business Development Manager
Base Salary: $140,000
Annual Bonus: 20%
Equity: 20,000 stock options
Signing Bonus: $5,000
Location: San Diego, CA
🍎Trebla’s Pick
Meet candidate 9449: Senior Medical Director, Clinical Development, Board-Certified Dermatologist, Residency and Fellowship from UCLA Division of Dermatology.
This candidate is a board-certified Dermatologist with over 10 years of experience in clinical drug development across multiple dermatologic indications (atopic dermatitis, acne, non-melanoma skin cancer, melasma, seborrheic keratoses, tinea pedis, onychomycosis, tinea versicolor, anti-aging). From pre-clinical, Phase I, and Phase II.
Board-certified Dermatologist
Clinical lead for 2 phase II Atopic Dermatitis studies
Early and late-stage experience (I-III)
Bulk of career spent at small biotech companies
Targeting base salary of ~$375k
🔎 Active searches
REGULATORY AFFAIRS
Vice President, Regulatory Affairs – Ophthalmology (San Francisco, CA)
Director, Regulatory Affairs - Gene Therapy for Neuromuscular diseases (Boston, MA)
Director, Regulatory CMC – Gene Therapy (Boston, MA)
Associate Director, Regulatory Affairs – Rare Disease (South San Francisco, CA)
Senior Manager, Regulatory Affairs – Rare Disease (South San Francisco, CA)
CLINICAL DEVELOPMENT
Executive Director, Clinical Development – Allergy/Dermatology (Boston, MA)
Senior Director, Clinical Development – Immunology/Dermatology (New Jersey)
Medical Director, Clinical Development – Oncology (Boston)
CLINICAL SCIENCE
Associate Director, Clinical Science – Neuromuscular (Boston, MA)
R&D
Head of In Vivo – Antibody Discovery (Boulder, CO)
Senior Research Associate – Antibody Discovery (Boulder, CO)
T R I B E
Here’s what the Trebla team’s been doing off the clock
Both Dakota and Natalia kick off their wedding seasons, Dakota staying local in the NY area, and Natalia more notably venturing back to Tuscany, Italy. Along the way, Natalia picked up more than just memories; let’s just say the local parking authorities also left her a little “souvenir".
